Reviewer's report
Title:Gynecomastia during imatinib mesylate treatment for gastrointestinal
tumor: a rare adverse event
Version: 1Date:22 June 2011
Reviewer: Giovanni Caocci
Reviewer's report:
This is an interesting report of patients experiencing gynecomastia during
imatinib treatment for gastrointestinal tumor. Only two reports have previously
decrypted such cases.
In order to judge the case for its impact on future therapy, the Authors will need
to add some data which, unfortunately, are missing.
Major compulsory revisions:
1. Full spectrum of steroid hormones and stimulating hormones (as published by
Gambacorti et al.) before and after tamoxifene treatment should be provided: in
particular, if possible, 17-OHP levels
2. The potential impact of first and second generation TKI on gynecomastia
should be discussed (not only imatinib)
Furthermore, I have the following minor essential revisions:
1. Abstract: In the results section it is not clear to which patients the authors are
referring when they speak about serum free testosterone levels (those with or
without gynecomastia?)
2. Introduction: please also consider the reported relationship between Dasatinib
and gynecomastia
3. Please provide schedule and duration of tamoxifene treatment.
4. Also provide any additional medication with the potential to influence hormonal
levels by interacting with imatinib (e.g., spironolactone)
5. Alternative treatments of gynecomastia should be discussed, e.g. radiation,
considering the interaction of tamoxifen with imatinib.
6. The English language needs to be “polished”. Throughout the paper some
verbs need to be corrected. The paper needs to be corrected by an English
mother tongue assistant.
Level of interest: An article whose findings are important to those with closely
related research interests
Quality of written English: Needs some language corrections before being
published
Statistical review: No, the manuscript does not need to be seen by a
statistician.
Declaration of competing interests:
I declare that I have no competing interests
Reviewer's report
Title:Gynecomastia during imatinib mesylate treatment for gastrointestinal
tumor: a rare adverse event
Version: 1Date:22 June 2011
Reviewer: Giovanni Caocci
Reviewer's report:
This is an interesting report of patients experiencing gynecomastia during
imatinib treatment for gastrointestinal tumor. Only two reports have previously
decrypted such cases.
In order to judge the case for its impact on future therapy, the Authors will need
to add some data which, unfortunately, are missing.
Major compulsory revisions:
1. Full spectrum of steroid hormones and stimulating hormones (as published by
Gambacorti et al.) before and after tamoxifene treatment should be provided: in
particular, if possible, 17-OHP levels
2. The potential impact of first and second generation TKI on gynecomastia
should be discussed (not only imatinib)
Furthermore, I have the following minor essential revisions:
1. Abstract: In the results section it is not clear to which patients the authors are
referring when they speak about serum free testosterone levels (those with or
without gynecomastia?)
2. Introduction: please also consider the reported relationship between Dasatinib
and gynecomastia
3. Please provide schedule and duration of tamoxifene treatment.
4. Also provide any additional medication with the potential to influence hormonal
levels by interacting with imatinib (e.g., spironolactone)
5. Alternative treatments of gynecomastia should be discussed, e.g. radiation,
considering the interaction of tamoxifen with imatinib.
6. The English language needs to be “polished”. Throughout the paper some
verbs need to be corrected. The paper needs to be corrected by an English
mother tongue assistant.
Level of interest: An article whose findings are important to those with closely
related research interests
Quality of written English: Needs some language corrections before being
published
Statistical review: No, the manuscript does not need to be seen by a
statistician.
Declaration of competing interests:
I declare that I have no competing interests
Please review this paper.
user
Reviewer's report
Title:Gynecomastia during imatinib mesylate treatment for gastrointestinal
tumor: a rare adverse event
Version: 1Date:22 June 2011
Reviewer: Giovanni Caocci
Reviewer's report:
This is an interesting report of patients experiencing gynecomastia during
imatinib treatment for gastrointestinal tumor. Only two reports have previously
decrypted such cases.
In order to judge the case for its impact on future therapy, the Authors will need
to add some data which, unfortunately, are missing.
Major compulsory revisions:
1. Full spectrum of steroid hormones and stimulating hormones (as published by
Gambacorti et al.) before and after tamoxifene treatment should be provided: in
particular, if possible, 17-OHP levels
2. The potential impact of first and second generation TKI on gynecomastia
should be discussed (not only imatinib)
Furthermore, I have the following minor essential revisions:
1. Abstract: In the results section it is not clear to which patients the authors are
referring when they speak about serum free testosterone levels (those with or
without gynecomastia?)
2. Introduction: please also consider the reported relationship between Dasatinib
and gynecomastia
3. Please provide schedule and duration of tamoxifene treatment.
4. Also provide any additional medication with the potential to influence hormonal
levels by interacting with imatinib (e.g., spironolactone)
5. Alternative treatments of gynecomastia should be discussed, e.g. radiation,
considering the interaction of tamoxifen with imatinib.
6. The English language needs to be “polished”. Throughout the paper some
verbs need to be corrected. The paper needs to be corrected by an English
mother tongue assistant.
Level of interest: An article whose findings are important to those with closely
related research interests
Quality of written English: Needs some language corrections before being
published
Statistical review: No, the manuscript does not need to be seen by a
statistician.
Declaration of competing interests:
I declare that I have no competing interests
assistant